Victrex (GB:VCT) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Victrex plc has announced a partnership with Maxx Orthopedics Inc, receiving FDA approval for a clinical study of their innovative PEEK-OPTIMA™ Femoral Knee Component in the US. This study aims to demonstrate the advantages of the PEEK Knee system over traditional metal components, building on positive international trials. The company anticipates entering the Indian market in 2025, with further interest from the medical device industry globally.
For further insights into GB:VCT stock, check out TipRanks’ Stock Analysis page.

